NCT04888949View on ClinicalTrials.gov

A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

May 18, 2023

Study Completion Date

May 18, 2023

Conditions
SARS-CoV-2 Infection( COVID-19 )
Interventions
BIOLOGICAL

Mesenchymal stem cell

1\*10\^8 cells are administered once a week, total four times intravenously.

BIOLOGICAL

Placebo

Commercially available saline.

Trial Locations (1)

565-0871

Osaka University Hospital, Suita

All Listed Sponsors
lead

Rohto Pharmaceutical Co., Ltd.

INDUSTRY